Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986178
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intratumoral
01
Overview
BMS-986178 is a fully human IgG1 monoclonal antibody that acts as an agonist of the OX40 receptor (also known as CD134 or TNFRSF4), a co-stimulatory receptor expressed on activated T cells. By binding to and activating OX40, BMS-986178 mimics the action of the endogenous OX40 ligand, leading to increased proliferation and survival of T cells, thereby enhancing immune responses against tumors. It is being developed primarily for the treatment of advanced solid tumors and has been evaluated both as monotherapy and in combination with immune checkpoint inhibitors such as nivolumab (anti-PD1) and ipilimumab (anti–CTLA4). The drug is currently in early-phase clinical trials for various solid tumor indications[1][2][3][5][7].
- Other names
- anti-OX40 antibody BMS 986178anti-OX-40 antibody BMS 986178anti-OX 40 antibody BMS 986178
02
Targets
CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on BMS-986178.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986178.